222 related articles for article (PubMed ID: 18715216)
1. Pramlintide reduces the risks associated with glucose variability in type 1 diabetes.
Kovatchev BP; Crean J; McCall A
Diabetes Technol Ther; 2008 Oct; 10(5):391-6. PubMed ID: 18715216
[TBL] [Abstract][Full Text] [Related]
2. A novel analytical method for assessing glucose variability: using CGMS in type 1 diabetes mellitus.
McCall AL; Cox DJ; Crean J; Gloster M; Kovatchev BP
Diabetes Technol Ther; 2006 Dec; 8(6):644-53. PubMed ID: 17109596
[TBL] [Abstract][Full Text] [Related]
3. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
Riddle MC; Nahra R; Han J; Castle J; Hanavan K; Hompesch M; Huffman D; Strange P; Öhman P
Diabetes Care; 2018 Nov; 41(11):2346-2352. PubMed ID: 30213882
[TBL] [Abstract][Full Text] [Related]
4. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
Singh-Franco D; Robles G; Gazze D
Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
[TBL] [Abstract][Full Text] [Related]
5. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
[TBL] [Abstract][Full Text] [Related]
6. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.
Heptulla RA; Rodriguez LM; Bomgaars L; Haymond MW
Diabetes; 2005 Apr; 54(4):1100-7. PubMed ID: 15793249
[TBL] [Abstract][Full Text] [Related]
7. Minimal reduction in insulin dosage with pramlintide therapy when pretreatment near-normal glycemia is established and square-wave meal bolus is used.
King AB
Endocr Pract; 2009 Apr; 15(3):229-33. PubMed ID: 19364691
[TBL] [Abstract][Full Text] [Related]
8. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.
Nyholm B; Orskov L; Hove KY; Gravholt CH; Møller N; Alberti KG; Moyses C; Kolterman O; Schmitz O
Metabolism; 1999 Jul; 48(7):935-41. PubMed ID: 10421239
[TBL] [Abstract][Full Text] [Related]
9. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
[TBL] [Abstract][Full Text] [Related]
10. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
Fineman MS; Koda JE; Shen LZ; Strobel SA; Maggs DG; Weyer C; Kolterman OG
Metabolism; 2002 May; 51(5):636-41. PubMed ID: 11979398
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
Edelman S; Garg S; Frias J; Maggs D; Wang Y; Zhang B; Strobel S; Lutz K; Kolterman O
Diabetes Care; 2006 Oct; 29(10):2189-95. PubMed ID: 17003291
[TBL] [Abstract][Full Text] [Related]
12. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes.
Ceriello A; Piconi L; Quagliaro L; Wang Y; Schnabel CA; Ruggles JA; Gloster MA; Maggs DG; Weyer C
Diabetes Care; 2005 Mar; 28(3):632-7. PubMed ID: 15735200
[TBL] [Abstract][Full Text] [Related]
13. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Whitehouse F; Kruger DF; Fineman M; Shen L; Ruggles JA; Maggs DG; Weyer C; Kolterman OG
Diabetes Care; 2002 Apr; 25(4):724-30. PubMed ID: 11919132
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.
Ratner R; Whitehouse F; Fineman MS; Strobel S; Shen L; Maggs DG; Kolterman OG; Weyer C
Exp Clin Endocrinol Diabetes; 2005 Apr; 113(4):199-204. PubMed ID: 15891954
[TBL] [Abstract][Full Text] [Related]
15. Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus.
Hassan K; Heptulla RA
Pediatr Diabetes; 2009 Jun; 10(4):264-8. PubMed ID: 19140902
[TBL] [Abstract][Full Text] [Related]
16. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
Ryan GJ; Jobe LJ; Martin R
Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
[TBL] [Abstract][Full Text] [Related]
17. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes.
Weinzimer SA; Sherr JL; Cengiz E; Kim G; Ruiz JL; Carria L; Voskanyan G; Roy A; Tamborlane WV
Diabetes Care; 2012 Oct; 35(10):1994-9. PubMed ID: 22815298
[TBL] [Abstract][Full Text] [Related]
18. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
Levetan C; Want LL; Weyer C; Strobel SA; Crean J; Wang Y; Maggs DG; Kolterman OG; Chandran M; Mudaliar SR; Henry RR
Diabetes Care; 2003 Jan; 26(1):1-8. PubMed ID: 12502651
[TBL] [Abstract][Full Text] [Related]
19. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
Riddle M; Frias J; Zhang B; Maier H; Brown C; Lutz K; Kolterman O
Diabetes Care; 2007 Nov; 30(11):2794-9. PubMed ID: 17698615
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the post-meal glucose response to different insulin bolus waveforms in insulin pump- and pre-meal pramlintide-treated type 1 diabetes patients.
King AB
Diabetes Technol Ther; 2010 Feb; 12(2):105-8. PubMed ID: 20105039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
